Titan Pharmaceuticals (NASDAQ: TTNP) is one of 106 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Titan Pharmaceuticals to related businesses based on the strength of its risk, earnings, valuation, institutional ownership, profitability, analyst recommendations and dividends.
This table compares Titan Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Titan Pharmaceuticals Competitors||-8,316.86%||-75.40%||-24.08%|
This is a breakdown of recent ratings and target prices for Titan Pharmaceuticals and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Titan Pharmaceuticals Competitors||641||2219||5389||219||2.61|
Titan Pharmaceuticals presently has a consensus target price of $2.00, suggesting a potential upside of 399.25%. As a group, “Biological products, except diagnostic” companies have a potential upside of 35.14%. Given Titan Pharmaceuticals’ higher probable upside, equities analysts plainly believe Titan Pharmaceuticals is more favorable than its peers.
Valuation & Earnings
This table compares Titan Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Titan Pharmaceuticals||$220,000.00||-$14.30 million||-0.57|
|Titan Pharmaceuticals Competitors||$1.02 billion||$93.10 million||-4.69|
Titan Pharmaceuticals’ peers have higher revenue and earnings than Titan Pharmaceuticals. Titan Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
12.2% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 19.5% of Titan Pharmaceuticals shares are owned by company insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility and Risk
Titan Pharmaceuticals has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Titan Pharmaceuticals’ peers have a beta of 1.64, meaning that their average share price is 64% more volatile than the S&P 500.
Titan Pharmaceuticals peers beat Titan Pharmaceuticals on 9 of the 13 factors compared.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. The company has a collaboration with Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients. Titan Pharmaceuticals, Inc. was founded in 1992 and is based in South San Francisco, California.
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.